ENSIGN: Phase II Window of Opportunity Trial of Stereotactic Body Radiation Therapy and In Situ Gene Therapy Followed by Nivolumab in Metastatic Squamous or Non-Squamous Non-Small Cell Lung Carcinoma and Metastatic Uveal Melanoma

Trial Profile

ENSIGN: Phase II Window of Opportunity Trial of Stereotactic Body Radiation Therapy and In Situ Gene Therapy Followed by Nivolumab in Metastatic Squamous or Non-Squamous Non-Small Cell Lung Carcinoma and Metastatic Uveal Melanoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Mar 2018

At a glance

  • Drugs Aglatimagene besadenovec (Primary) ; Nivolumab (Primary) ; Valaciclovir (Primary)
  • Indications Non-small cell lung cancer; Uveal melanoma
  • Focus Therapeutic Use
  • Acronyms ENSIGN
  • Most Recent Events

    • 08 Mar 2018 Planned number of patients changed from 29 to 25.
    • 05 Apr 2017 Trial design presented at the 108th Annual Meeting of the American Association for Cancer Research
    • 15 Feb 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top